미국의 누트로픽 시장 규모, 점유율 및 동향 분석 보고서 : 제형별, 유통 채널별, 주요 기업 및 경쟁 분석 및 부문별 예측(2026-2033년)

U.S. Nootropics Market Summary

The U.S. nootropics market size was valued at USD 1.81 billion in 2025 and is projected to grow from USD 1.98 billion in 2026 to USD 4.26 billion by 2033, at a CAGR of 11.6% from 2026 to 2033. Rising interest in proactive health management, particularly among aging populations, is driving demand for cognitive support products.

At the same time, professionals and students operating in competitive environments are seeking improved focus, memory, and concentration. Increasing acceptance of natural and herbal supplements over pharmaceuticals is further enhancing the appeal of nootropics marketed as brain-boosting solutions.

The nootropics industry is driven by rising demand for cognitive enhancement products among professionals and students seeking better focus, memory, and overall mental performance. Growing awareness of age-related cognitive decline and neurodegenerative conditions has further broadened the consumer base, supporting demand across wider age groups. In addition, advancements in neuropharmacology and bioactive ingredients are enabling the development of more effective and targeted formulations.

The industry is also benefiting from the rapid expansion of e-commerce platforms and direct to consumer supplement brands, which have significantly improved product accessibility and global reach. At the same time, companies are increasingly entering strategic partnerships and collaborations to strengthen product portfolios, leverage scientific expertise, and accelerate innovation in cognitive wellness solutions. For example, in August 2024, Paradigm Sports partnered with Ten Percent Club to promote nootropics among professional athletes and sports enthusiasts. The partnership focuses on increasing awareness of cognitive-enhancing supplements and expanding adoption in sports performance and mental focus applications.

The nootropics market is gaining strong momentum as rising consumer awareness of mental health and cognitive wellness increases demand for products that support focus, memory, mood, and overall brain performance. In the U.S. nootropics industry, growing stress levels, remote work lifestyles, and academic pressure are expanding adoption across students, working professionals, and older adults seeking to maintain mental sharpness. Consumers are increasingly looking for effective daily cognitive support solutions backed by science. This trend is creating opportunities for brands to position clinically supported formulations that address productivity, concentration, and long-term brain health.

Another major opportunity in the U.S. nootropics industry lies in personalized nutrition and biohacking trends. Consumers are seeking solutions tailored to their specific cognitive goals, encouraging companies to introduce customizable supplement stacks, targeted ingredient blends, and subscription-based models. These offerings improve convenience, customer retention, and recurring revenue streams. Strong e-commerce adoption is further accelerating this shift, as online platforms make product discovery, education, and repeat purchases easier. Subscription-led direct-to-consumer strategies are particularly effective in building long-term brand loyalty while lowering customer acquisition costs.

Innovation in delivery formats is also expanding the addressable market within the nootropics industry. Beyond traditional capsules, companies are launching gummies, powders, functional beverages, and ready-to-drink shots to appeal to convenience-focused and wellness-oriented consumers. These formats help integrate nootropics into daily routines such as morning energy rituals, fitness recovery, and workplace productivity habits. Functional beverages infused with ingredients such as mushrooms, adaptogens, and natural stimulants are gaining notable traction.

In addition, partnerships with fitness, wellness, and lifestyle brands present a valuable growth avenue for the U.S. market. Collaborations can improve brand visibility, create new retail channels, and position nootropic products as part of broader health and performance ecosystems. As consumer interest in preventive wellness continues to rise, product innovation, personalization, and lifestyle integration are expected to remain key growth drivers for the U.S. nootropics industry.

U.S. Nootropics Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. nootropics market report based on the form, and distribution channel.

• Form Outlook (Revenue, USD Billion, 2021 - 2033)
• Capsules/Tablets
• Powder
• Drinks
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Offline
• Online

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Materials & Third-Party Perspectives
  • 1.3.4. Primary Research
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Data Visualization
• 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Form Outlook
• 2.3. Distribution Channel Outlook
• 2.4. Competitive Landscape Snapshot

Chapter 3. U.S. Nootropics Market Variables and Trends

• 3.1. Market Introduction
• 3.2. Industry Value Chain Analysis
  • 3.2.1. Raw Material Trends & Outlook
  • 3.2.2. Retail/Sales Channel Analysis
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
  • 3.3.3. Market Opportunities
  • 3.3.4. Market Challenges
• 3.4. Industry Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
• 3.5. Market Entry Strategies

Chapter 4. U.S. Nootropics Market: Consumer Behavior Analysis

• 4.1. Demographic Analysis
• 4.2. Consumer Trends & Preferences
• 4.3. Factors Affecting Buying Decisions
• 4.4. Consumer Product Adoption
• 4.5. Observations & Recommendations

Chapter 5. U.S. Nootropics Market: Form Estimates & Trend Analysis

• 5.1. U.S. Nootropics Market, By Form: Key Takeaways
• 5.2. Form Movement Analysis & Market Share, 2025 & 2033
• 5.3. Market Estimates & Forecasts by Form, 2021 - 2033 (USD Billion)
  • 5.3.1. Capsules/Tablets
    • 5.3.1.1. Market estimates and forecast, 2021 - 2033 (USD Billion)
  • 5.3.2. Powder
    • 5.3.2.1. Market estimates and forecast, 2021 - 2033 (USD Billion)
  • 5.3.3. Drinks
    • 5.3.3.1. Market estimates and forecast, 2021 - 2033 (USD Billion)
  • 5.3.4. Other
    • 5.3.4.1. Market estimates and forecast, 2021 - 2033 (USD Billion)

Chapter 6. U.S. Nootropics Market: Distribution Channel Estimates & Trend Analysis

• 6.1. U.S. Nootropics Market, By Distribution Channel: Key Takeaways
• 6.2. Distribution Channel Movement Analysis & Market Share, 2025 & 2033
• 6.3. Market Estimates & Forecasts by Distribution Channel, 2021 - 2033 (USD Billion)
  • 6.3.1. Offline
    • 6.3.1.1. Market estimates and forecast, 2021 - 2033 (USD Billion)
  • 6.3.2. Online
    • 6.3.2.1. Market estimates and forecast, 2021 - 2033 (USD Billion)

Chapter 7. U.S. Nootropics Market: Competitive Analysis

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Participant's Overview
• 7.4. Financial Performance
• 7.5. Product Benchmarking
• 7.6. Company Market Share Analysis, 2025 (%)
• 7.7. Company Heat Map Analysis
• 7.8. Strategy Mapping
• 7.9. Company Profiles
  • 7.9.1. Onnit Labs, Inc. (Uniliver)
    • 7.9.1.1. Company Overview
    • 7.9.1.2. Financial Performance
    • 7.9.1.3. Product Portfolios
    • 7.9.1.4. Strategic Initiatives
  • 7.9.2. Reckitt Benckiser Group PLC
    • 7.9.2.1. Company Overview
    • 7.9.2.2. Financial Performance
    • 7.9.2.3. Product Portfolios
    • 7.9.2.4. Strategic Initiatives
  • 7.9.3. Mind Lab Pro
    • 7.9.3.1. Company Overview
    • 7.9.3.2. Financial Performance
    • 7.9.3.3. Product Portfolios
    • 7.9.3.4. Strategic Initiatives
  • 7.9.4. TruBrain (TriplePulse)
    • 7.9.4.1. Company Overview
    • 7.9.4.2. Financial Performance
    • 7.9.4.3. Product Portfolios
    • 7.9.4.4. Strategic Initiatives
  • 7.9.5. Nooflux
    • 7.9.5.1. Company Overview
    • 7.9.5.2. Financial Performance
    • 7.9.5.3. Product Portfolios
    • 7.9.5.4. Strategic Initiatives
  • 7.9.6. Zhou Nutrition
    • 7.9.6.1. Company Overview
    • 7.9.6.2. Financial Performance
    • 7.9.6.3. Product Portfolios
    • 7.9.6.4. Strategic Initiatives
  • 7.9.7. Nootropics Depot
    • 7.9.7.1. Company Overview
    • 7.9.7.2. Financial Performance
    • 7.9.7.3. Product Portfolios
    • 7.9.7.4. Strategic Initiatives
  • 7.9.8. Neutonic
    • 7.9.8.1. Company Overview
    • 7.9.8.2. Financial Performance
    • 7.9.8.3. Product Portfolios
    • 7.9.8.4. Strategic Initiatives
  • 7.9.9. Amway Corp.
    • 7.9.9.1. Company Overview
    • 7.9.9.2. Financial Performance
    • 7.9.9.3. Product Portfolios
    • 7.9.9.4. Strategic Initiatives
  • 7.9.10. Natural Stacks
    • 7.9.10.1. Company Overview
    • 7.9.10.2. Financial Performance
    • 7.9.10.3. Product Portfolios
    • 7.9.10.4. Strategic Initiatives